Canakinumab investigated for treating familial Mediterranean fever

Expert Opinion on Biological Therapy

Volumn 16, Issue 11, 2016, Pages 1425-1434

  Haviv, Ruby ^a,b   Hashkes, Philip J ^a,c  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

Amyloidosis; anakinra; canakinumab; colchicine; familial Mediterranean fever; interleukin 1; pyrin; rilonacept; treatment

Indexed keywords

CANAKINUMAB; COLCHICINE; INTERLEUKIN 1BETA; PLACEBO; RILONACEPT;

ACCUMULATION INDEX; ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; FAMILIAL MEDITERRANEAN FEVER; HUMAN; PATIENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84988430906     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2016.1233963     Document Type: Article

References (61)

1. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90:797–807.
2. The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17:25–31. DOI:10.1038/ng0997-25
3. Barron KS, Kastner DL. Familial Mediterranean fever. In Petty RE, Laxer RM, Lindsley CB, et al. Textbook of pediatric rheumatology. 7th ed. Elsevier, Philadelphia, PA; 2015. p. 609–613.
4. E.Ben-Chetrit, I.Touitou Familial Mediterranean fever in the world. Arthritis Rheum. 2009;61:1447–1453.• This study is the best estimate of the worldwide prevalence of FMF, which is important for assessing the potential population in need of IL-l inhibitors.
5. E.Sohar, J.Gafni, M.Pras, et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43:227–253.• This large series is the classic clinical description of FMF.
6. A.Livneh, P.Langevitz, D.Zemer, et al. The changing face of familial Mediterranean fever. Semin Arthritis Rheum. 1996;26:612–627.
7. F.Yalcinkaya, S.Ozen, Z.B.Ozcakar, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009;48:395–398. DOI:10.1093/rheumatology/ken509
8. A.Livneh, P.Langevitz, D.Zemer, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40:1879–1885. DOI:10.1002/1529-0131(199710)40:10<1879::AID-ART23>3.0.CO;2-M
9. E.Ben-Chetrit, M.Levy. Familial Mediterranean fever. Lancet. 1998;351:659–664. DOI:10.1016/S0140-6736(97)09408-7
10. P.J.Hashkes, S.J.Spalding, R.Hajj-Ali, et al. The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Biomed Res Int. 2014;2014:854842. DOI:10.1155/2014/854842
11. N.Tidow, X.Chen, C.Muller, et al. Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood. 2000;95:1451–1455.
12. J.J.Chae, G.Wood, S.L.Masters, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc Natl Acad Sci USA. 2006;103:9982–9987. DOI:10.1073/pnas.0602081103•• This important translational study clarifies the rational of using IL-1 inhibition in FMF.
13. J.J.Chae, Y.H.Cho, G.S.Lee, et al. Gain-of-function pyrin mutations induce NLRP3 protein independent interleukin-1β activation and severe autoinflammation in mice. Immunity. 2011;34:755–768. DOI:10.1016/j.immuni.2011.02.020• This study offers new insights to the role of pyrin mutations in causing IL-1β-induced inflammation.
14. Y.H.Park, G.Wood, D.L.Kastner, et al. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016;17:914–921.•• This innovative study defines common mechanisms for various autoinflammatory diseases resulting in increased IL-1 activation via the pyrin inflammasome.
15. S.E.Goldfinger. Colchicine for familial Mediterranean fever [letter]. N Engl J Med. 1972;287:1302. DOI:10.1056/NEJM197212212872514• This Letter to the Editor led to the discovery that colchicine is effective in FMF and revolutionized treatment of this disease.
16. M.Lidar, A.Livneh. Familial Mediterranean fever:clinical, molecular and management advancements. Neth J Med. 2007;65:318–324.
17. E.Demirkaya, B.Erer, S.Ozen, et al. Efficacy and safety of treatments in familial Mediterranean fever:a systematic review. Rheumatol Int. 2016;36:325–331. DOI:10.1007/s00296-015-3408-9• This study reviews the controlled trials in FMF from 1974 to 2015 but does not include the anakinra and canakinumab trials.
18. A.Slobodnick, B.Shah, M.H.Pillinger, et al. Colchicine:old and new. Am J Med. 2015;128:461–470. DOI:10.1016/j.amjmed.2014.12.010
19. N.Ter Haar, H.Lachmann, S.Ozen, et al. Treatment of autoinflammatory diseases:results from the eurofever registry and a literature review. Ann Rheum Dis. 2013;72:678–685. DOI:10.1136/annrheumdis-2011-201268• This large registry study describes the ‘real-world’ response to colchicine and others treatments used in FMF and other autoinflammatory syndromes.
20. E.Seyahi, H.Ozdogan, S.Celik, et al. Treatment options in colchicine resistant familial Mediterranean fever patients:thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol. 2006;24(Suppl 42):S99–S103.
21. S.A.Bilgen, L.Kilic, A.Akdogan, et al. Effects of anti-tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol. 2011;17:358–362. DOI:10.1097/RHU.0b013e31823682f5
22. M.Tunca, S.Akar, M.Soytürk, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever:a double-blind, placebo-controlled trial. Clin Exp Rheumatol. 2004;22(Suppl 34):S37–S40.
23. R.Belkhir, L.Moulonguet-Doleris, E.Hachulla, et al. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med. 2007;146:825–826.
24. R.Gattringer, H.Lagler, K.B.Gattringer, et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever:effective but risky. Eur J Clin Invest. 2007;37:912–914. DOI:10.1111/j.1365-2362.2007.01868.x
25. L.M.Kuijk, A.M.Govers, J.Frenkel, et al. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis. 2007;66:1545–1546. DOI:10.1136/ard.2007.071498
26. R.Roldan, A.M.Ruiz, M.D.Miranda, et al. Anakinra:new therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine. 2008;75:504–505. DOI:10.1016/j.jbspin.2008.04.001
27. L.Calligaris, F.Marchetti, A.Tommasini, et al. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr. 2008;167:695–696. DOI:10.1007/s00431-007-0547-3
28. I.Mitroulis, V.P.Papadopoulos, T.Konstantinidis, et al. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med. 2008;66:489–491.
29. C.Moser, G.Pohl, I.Haslinger, et al. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transplant. 2009;24:676–678. DOI:10.1093/ndt/gfn646
30. Y.Bilginer, N.A.Ayaz, S.Ozen. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol. 2010;29:209–210. DOI:10.1007/s10067-009-1279-8
31. S.Hennig, K.Bayegan, M.Uffmann, et al. Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra – case report and review. Rheumatol Int. 2012;32:1801–1804. DOI:10.1007/s00296-010-1429-y
32. N.Alpay, A.Sumnu, Y.Caliskan, et al. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int. 2012;32:3277–3279. DOI:10.1007/s00296-010-1474-6
33. C.Estublier, K.Stankovic Stojanovic, J.F.Bergerot, et al. Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. Joint Bone Spine. 2013;80:645–649. DOI:10.1016/j.jbspin.2013.03.004
34. R.Mercan, A.Turan, B.Bitik, et al. Rapid resolution of protracted febrile myalgia syndrome with anakinra:report of two cases. Mod Rheumatol. 2016;26:458–459. DOI:10.3109/14397595.2014.882221
35. Á.M.Sevillano, E.Hernandez, E.Gonzalez, et al. Anakinra induces complete remission of nephrotic syndrome in a patient with familial Mediterranean fever and amyloidosis. Nefrologia. 2016;36:63–66. DOI:10.1016/j.nefro.2015.06.026
36. S.Ozen, Y.Bilginer, N.Aktay Ayaz, et al. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38:516–551. DOI:10.3899/jrheum.100718
37. U.Meinzer, P.Quartier, J.F.Alexandra, et al. Interleukin-1 targeting drugs in familial Mediterranean fever:a case series and a review of the literature. Semin Arthritis Rheum. 2011;41:265–271. DOI:10.1016/j.semarthrit.2010.11.003
38. K.Stankovic Stojanovic, Y.Delmas, P.U.Torres, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant. 2012;27:1898–1901. DOI:10.1093/ndt/gfr528
39. L.Rossi-Semerano, B.Fautrel, D.Wendling, et al. [MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study group on behalf of CRI (Club Rhumatisme et Inflammation)]. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France:a nationwide survey. Orphanet J Rare Dis. 2015;10:19. DOI:10.1186/s13023-015-0228-7
40. P.Cetin, I.Sari, B.Sozeri, et al. Efficacy of interleukin-1 targeting treatments in patients with familial Mediterranean fever. Inflammation. 2015;38:27–31. DOI:10.1007/s10753-014-0004-1
41. Ö.Başaran, N.Uncu, B.A.Çelikel, et al. Interleukin-1 targeting treatment in familial Mediterranean fever:an experience of pediatric patients. Mod Rheumatol. 2015;25:621–624. DOI:10.3109/14397595.2014.987437
42. F.K.Eroglu, N.Beşbaş, R.Topaloglu, et al. Treatment of colchicine-resistant familial Mediterranean fever in children and adolescents. Rheumatol Int. 2015;35:1733–1737. DOI:10.1007/s00296-015-3293-2
43. Z.B.Özçakar, S.Özdel, S.Yilmaz, et al. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. 2016;35:441–446. DOI:10.1007/s10067-014-2772-2
44. P.J.Hashkes, S.J.Spalding, E.H.Giannini, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever:a randomized trial. Ann Intern Med. 2012;157:533–541. DOI:10.7326/0003-4819-157-8-201210160-00003• This was the first controlled trial showing the efficacy of anti-IL-1 therapy in colchicine-resistant FMF.
45. I.Mitroulis, P.Skendros, A.Oikonomou, et al. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and long standing destructive arthritis. Ann Rheum Dis. 2011;70:1347–1348. DOI:10.1136/ard.2010.146878
46. D.O.Hacihamdioglu, S.Ozen. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology (Oxford). 2012;51:1041. DOI:10.1093/rheumatology/ker154
47. M.Alpa, D.Roccatello. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment. Drug Des Devel Ther. 2015;9:1983–1987. DOI:10.2147/DDDT.S69117
48. R.Brik, Y.Butbul-Aviel, S.Lubin, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever:a 6-month open-label, single-arm pilot study. Arthritis Rheumatol. 2014;66:3241–3243. DOI:10.1002/art.38777•• This paper describes the phase II canakinumab trial in Israeli children.
49. A.Gül, H.Ozdogan, B.Erer, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015;17:243. DOI:10.1186/s13075-015-0765-4•• This paper describes the phase II canakinumab trial in Turkish adolescents and adults.
50. I.Ben-Zvi, A.Livneh. Colchicine failure in familial Mediterranean fever and potential alternatives:embarking on the anakinra trial. Isr Med Assoc J. 2014;16:271–27.
51. I.Ben-Zvi, O.Kukay, E.Giat, et al. Anakinra for colchicine resistant FMF – A randomized, double blinded, placebo-controlled trial [abstract]. Isr Soc of Rheumatol Annual Meeting Proc. 2016;23.• This abstract, not yet published as a full paper, describes the controlled trial of anakinra in patients with colchicine-resistant FMF.
52. F.De Benedetti, J.Anton, M.Gattorno, et al. A phase III, pivotal, umbrella trial of canakinumab in patients with auto-inflammatory periodic fever syndromes [abstract]. Ann Rheum Dis. 2016;75(suppl 2):615–616.•• This abstracts describes the design and initial results of the pivotal placebo-controlled, randomized, treatment epoch of the phase III canakinumab trial.
53. F.De Benedetti, J.Anton, M.Gattorno, et al. Pharmacokinetics and pharmacodynamics of canakinumab in patients with auto-inflammatory periodic fever syndromes (colchicine-resistant FMF, HIDS/MKD and TRAPS) [abstract]. Ann Rheum Dis. 2016;75(suppl 2):397–398.• This abstract describes the pharmacokinetics and pharmacodynamics of canakinumab in FMF patients from the pivotal treatment epoch of the phase III canakinumab trial.
54. H.Lachmann, A.Simon, J.Anton, et al. Canakinumab improves patient reported outcomes in patients with periodic fever syndromes [abstract]. Ann Rheum Dis. 2016;75(suppl 2):616.• This abstract depicts the health-related quality of life results from the pivotal treatment epoch of the phase III canakinumab trial.
55. P.Portincasa. Colchicine, biologic agents and more for the treatment of familial Mediterranean fever. The old, the new, and the rare. Curr Med Chem. 2016;23:60–86.
56. L.D.Church, M.F.McDermott. Canakinumab, a fully-human mAb against IL-1β for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009;11:81–89.
57. Novartis. Ilaris prescribing information. cited 2016 Jun10. Available from:http://www.pharma.us.novartis.com/product/pi/pdf/ilaris.pdf
58. P.Hashkes, Y.Butbul Aviel, S.Lubin, et al. Long-term efficacy of canakinumab in childhood colchicine resistant familial Mediterranean fever [abstract]. Arthritis Rheumatol. 2014;66(suppl 3):S108. DOI:10.1002/art.38492
59. O.Toker, P.J.Hashkes. Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). Biologics. 2010;4:131–138.
60. U.A.Walker, H.M.Hoffman, R.Williams, et al. Severe inflammation following vaccination against streptococcus pneumoniae in patients with cryopyrin-associated periodic syndromes. Arthritis Rheumatol. 2016;68:516–520. DOI:10.1002/art.39482• This study describes a potential severe local reaction to pneumococcal vaccines which may be associated with canakinumab use in autoinflammatory diseases.
61. E.Demirkaya, C.Acikel, P.Hashkes, et al. for the FMF arthritis vasculitis and orphan disease research in pediatric rheumatology (FAVOR). Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis. 2016;75:1051–1056. DOI:10.1136/annrheumdis-2015-208671